M Álvarez-Salafranca,A Lapeña-Casado,M García-García et al.
M Álvarez-Salafranca et al.
RF - Biological treatments in familial benign pemphigus or Hailey-Hailey disease [0.03%]
生物制剂治疗Hailey-Hailey病或家庭性良性天疱疮研究进展
P Balado-Simó,M Mansilla-Polo,J M Mascaró Jr
P Balado-Simó
K Montserrat Ramirez-Gomez,A Imbernon-Moya,M F Villegas-Calzada et al.
K Montserrat Ramirez-Gomez et al.
Graying is a natural process, characterized by the loss of pigment in the hair, and is considered a sign of aging in society; its onset and progression is closely correlated with age and occurs to varying degrees in all individuals, regardl...
Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients [0.03%]
低剂量口服米诺地尔治疗COVID-19相关休止期脱发：69例患者回顾性系列研究结果
C D Villarreal-Villarreal,E Boland-Rodriguez,D Mares-Custodio et al.
C D Villarreal-Villarreal et al.
Background and objective: Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although i...
Foundation Models in Dermatology: Advances in Artificial Intelligence. A Narrative Review [0.03%]
皮肤科基础模型：人工智能进展。叙述性综述
D Emilio Pimienta-Rosero,E Yesid Benavides-Tulcán,D C Fajardo-Murcia
D Emilio Pimienta-Rosero
Foundation models (FMs) are deep learning models distinguished by their extensive training data and adaptability to a variety of medical tasks including disease classification, monitoring, risk stratification and treatment planning. They ar...
M Prados-Castaño,M Reguero Capilla,E Menéndez-Rivero et al.
M Prados-Castaño et al.
Y C Sobrino-García,C Carrión-García,A Garrido-Ríos et al.
Y C Sobrino-García et al.
TOXIC EPIDERMAL NECROLYSIS DUE TO PEMBROLIZUMAB-ASSOCIATED CHEMOTHERAPY [0.03%]
与派姆单抗相关的化疗所致的大疱性表皮松解坏死型药疹
L Bernal Masferrer,B Aldea Manrique,M Claudia Matei et al.
L Bernal Masferrer et al.
Fatima-Zahra Agharbi,Ghita Basri,Inas Chikhaoui et al.
Fatima-Zahra Agharbi et al.
Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study [0.03%]
Secukinumab治疗腋臭的现实世界经验：SECU-SPAIN研究的多中心回顾性分析（共263例患者）
A Martorell-Calatayud,E Vilarrasa-Rull,P Fernandez-Crehuet et al.
A Martorell-Calatayud et al.
Background/objective: There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety a...